Recurv is the 8th early-stage or product focused company (PFC) investment for TVM Life Science Innovation II Fund Recurv is developing novel taxane, RP-001, against solid tumors RP-001 delivered ...

MUNICH, Germany and MONTREAL, Jan. 31, 2024 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading transatlantic venture capital firm focused on investments in life sciences ...

Tristan de Boysson, Managing Partner of TVM Capital Healthcare, commented: "With this investment from our TVM Healthcare Afiyah Fund, we will accelerate the market introduction of a product which ...

MUNICH, Germany and MONTREAL, April 22, 2024 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, ...